Vesatolimod + VRC07523LS + CAP256V2LS
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HIV-1-infection
Conditions
HIV-1-infection
Trial Timeline
Jun 9, 2022 → Jan 16, 2025
NCT ID
NCT05281510About Vesatolimod + VRC07523LS + CAP256V2LS
Vesatolimod + VRC07523LS + CAP256V2LS is a phase 2 stage product being developed by Gilead Sciences for HIV-1-infection. The current trial status is completed. This product is registered under clinical trial identifier NCT05281510. Target conditions include HIV-1-infection.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05281510 | Phase 2 | Completed |
Competing Products
20 competing products in HIV-1-infection